Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

vemedia manufacturing b.v. verrijn stuartweg 60 1112 ax diemen - codeinediwaterstoffosfaat 0,5-water 0,5 mg/ml - stroop - citroenzuur 1-water (e 330) ; ethanol 96 % 10 mg/ml ; glucose, vloeibaar ; honing ; natriumbenzoaat (e 211) ; rozenolie ; saccharose ; tinctura melrosi ; tinctura thymi compositum ; water, gezuiverd, - combinations

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bmodesto b.v. - fentanyldiwaterstofcitraat samenstelling overeenkomend met ; fentanyl - tablet voor sublinguaal gebruik - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; siliciumdioxide (e 551), - fentanyl

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bmodesto b.v. minervaweg 2 8239 dl lelystad - fentanyldiwaterstofcitraat samenstelling overeenkomend met ; fentanyl - tablet voor sublinguaal gebruik - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; siliciumdioxide (e 551) - fentanyl

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bmodesto b.v. minervaweg 2 8239 dl lelystad - fentanyldiwaterstofcitraat samenstelling overeenkomend met ; fentanyl - tablet voor sublinguaal gebruik - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; siliciumdioxide (e 551) - fentanyl

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bmodesto b.v. minervaweg 2 8239 dl lelystad - fentanyldiwaterstofcitraat samenstelling overeenkomend met ; fentanyl - tablet voor sublinguaal gebruik - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; siliciumdioxide (e 551) - fentanyl

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bmodesto b.v. minervaweg 2 8239 dl lelystad - fentanyldiwaterstofcitraat samenstelling overeenkomend met ; fentanyl - tablet voor sublinguaal gebruik - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; magnesiumstearaat (e 470b) ; mannitol (d-) (e 421) ; siliciumdioxide (e 551)

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemorragische koorts, ebola - vaccins - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemorragische koorts, ebola - vaccins - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Europese Unie - Nederlands - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.